Your browser is no longer supported. Please, upgrade your browser.
ARCT Arcturus Therapeutics Holdings Inc. monthly Stock Chart
ARCT [NASD]
Arcturus Therapeutics Holdings Inc.
Index- P/E- EPS (ttm)-3.23 Insider Own22.20% Shs Outstand22.94M Perf Week28.03%
Market Cap1.83B Forward P/E- EPS next Y-0.57 Insider Trans-0.44% Shs Float18.92M Perf Month49.87%
Income-52.00M PEG- EPS next Q-0.88 Inst Own74.30% Short Float23.84% Perf Quarter45.34%
Sales10.30M P/S177.83 EPS this Y0.50% Inst Trans41.96% Short Ratio6.20 Perf Half Y90.91%
Book/sh11.41 P/B6.66 EPS next Y81.60% ROA-33.20% Target Price66.50 Perf Year612.28%
Cash/sh12.74 P/C5.97 EPS next 5Y- ROE-52.30% 52W Range8.51 - 66.24 Perf YTD599.17%
Dividend- P/FCF- EPS past 5Y33.70% ROI- 52W High14.73% Beta2.70
Dividend %- Quick Ratio11.20 Sales past 5Y- Gross Margin- 52W Low793.07% ATR6.33
Employees88 Current Ratio11.20 Sales Q/Q-30.30% Oper. Margin- RSI (14)71.60 Volatility10.57% 13.91%
OptionableYes Debt/Eq0.06 EPS Q/Q-62.60% Profit Margin- Rel Volume2.36 Prev Close60.63
ShortableYes LT Debt/Eq0.06 EarningsNov 09 AMC Payout- Avg Volume727.92K Price76.00
Recom1.80 SMA2040.16% SMA5051.61% SMA20092.38% Volume1,717,468 Change25.35%
Oct-26-20Initiated Barclays Overweight $72
Oct-06-20Initiated Citigroup Buy $65
Aug-26-20Initiated Piper Sandler Overweight $77
Jul-30-20Resumed ROTH Capital Buy $77
Jul-16-20Initiated Raymond James Outperform $72
Jul-13-20Initiated B. Riley FBR Buy
Jun-09-20Downgrade WBB Securities Buy → Hold
Feb-11-20Initiated Robert W. Baird Outperform $24
Feb-07-20Initiated Guggenheim Buy
Feb-06-20Initiated Guggenheim Buy
Apr-05-19Initiated H.C. Wainwright Buy $15
Sep-20-18Upgrade WBB Securities Buy → Strong Buy
Jan-22-18Initiated Chardan Capital Markets Buy $12
Nov-23-20 08:40AM  
Nov-17-20 06:04AM  
Nov-16-20 09:30AM  
Nov-11-20 05:16AM  
Nov-10-20 03:46PM  
08:31AM  
Nov-09-20 11:10PM  
05:15PM  
04:01PM  
02:30PM  
07:00AM  
Nov-04-20 08:00AM  
Nov-02-20 04:33PM  
Oct-31-20 06:08AM  
Oct-30-20 02:40PM  
09:00AM  
Oct-29-20 12:34PM  
07:21AM  
Oct-08-20 10:06AM  
Oct-05-20 09:50AM  
08:00AM  
Oct-01-20 08:00AM  
Sep-29-20 06:42AM  
Sep-18-20 12:15PM  
Sep-17-20 01:12PM  
Sep-08-20 08:30AM  
Sep-04-20 10:31AM  
Sep-03-20 08:40AM  
Aug-31-20 06:12PM  
Aug-30-20 10:09AM  
Aug-23-20 09:02AM  
Aug-18-20 09:00AM  
Aug-11-20 08:00AM  
Aug-10-20 05:25PM  
04:01PM  
Aug-07-20 10:35AM  
Aug-06-20 08:30AM  
Aug-04-20 08:30AM  
Aug-02-20 07:04AM  
Jul-31-20 04:01PM  
08:59AM  
Jul-29-20 12:30AM  
Jul-28-20 04:01PM  
Jul-24-20 07:15AM  
Jul-23-20 04:01PM  
Jul-21-20 08:30AM  
Jul-13-20 12:00PM  
Jul-05-20 02:25PM  
Jul-01-20 08:00AM  
Jun-29-20 08:00AM  
Jun-20-20 12:11PM  
Jun-16-20 12:06PM  
07:02AM  
Jun-11-20 08:00AM  
Jun-05-20 08:00AM  
Jun-04-20 07:27AM  
May-28-20 02:11PM  
May-27-20 12:35PM  
May-21-20 08:30AM  
May-12-20 08:53AM  
May-10-20 06:30AM  
May-08-20 09:30AM  
May-07-20 04:01PM  
May-04-20 03:00PM  
08:39AM  
Apr-27-20 07:00AM  
Apr-21-20 08:00AM  
Apr-16-20 09:10AM  
Apr-15-20 04:01PM  
Apr-13-20 08:00AM  
Apr-09-20 01:43PM  
07:00AM  
Mar-27-20 07:00AM  
Mar-14-20 08:17AM  
Mar-11-20 05:15PM  
04:01PM  
02:30PM  
Mar-06-20 09:32AM  
Mar-05-20 08:05AM  
Mar-04-20 12:30PM  
10:35AM  
07:30AM  
Feb-24-20 07:30AM  
Feb-19-20 07:30AM  
Jan-10-20 05:47AM  
Jan-08-20 07:00AM  
Dec-19-19 03:49PM  
Dec-11-19 02:45PM  
Nov-11-19 06:56AM  
Nov-07-19 04:01PM  
07:30AM  
Nov-04-19 07:30AM  
Oct-30-19 10:33AM  
Oct-08-19 09:00AM  
Oct-02-19 09:00AM  
08:31AM  
Sep-26-19 08:00AM  
Sep-23-19 08:00AM  
Sep-18-19 06:28AM  
Sep-04-19 09:42AM  
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the treatment of liver and respiratory care diseases. The company engages in the discovery and development of RNA medicines, including the production of RNA drug substance and nanoparticle-formulated drug product; and development of infectious disease vaccines using its Self-Transcribing and Replicating RNA (STARR) technology. Its preclinical drug discovery and development programs include LUNAR-OTC development program that is developing mRNA compounds to treat ornithine transcarbamylase (OTC) deficiency; LUNAR-CF program, which is developing mRNA compounds to replace dysfunctional cystic fibrosis transmembrane conductance regulator (CFTR) protein in cystic fibrosis (CF) patients; and LUNAR-CV and LUNAR-MD that are internal research programs focused on target validation of multiple pipeline LUNAR-mRNA program candidates. The company owns LUNAR and nucleic acid technologies that are covered by a patent portfolio of 182 patents and patent applications, issued in the United States, China, Europe, Japan, and other countries. It has collaboration partnerships with Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for certain rare disease targets; Millennium Pharmaceuticals, Inc. (Takeda) to develop a nucleic acid-based therapeutic candidate for the treatment of nonalcoholic steatohepatitis; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus infection; CureVac AG; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19, a vaccine to address the Coronavirus outbreak; and Catalent, Inc. to support the expected manufacture of Arcturus' COVID-19 mRNA vaccine candidate (LUNAR-COV19. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Chivukula PadChief Scientific Officer & COONov 02Sale55.2810,000552,800702,548Nov 03 08:01 PM
Chivukula PadChief Scientific Officer & COOOct 01Sale42.8310,000428,300712,548Oct 02 05:00 PM
Chivukula PadChief Scientific Officer & COOSep 03Sale45.1610,000451,600722,548Sep 04 05:05 PM
Kummerfeld Keith CSee RemarksJun 12Buy33.3345014,999950Jun 12 06:22 PM
Payne Joseph EPresident and CEOJun 10Buy31.691,00031,6901,475,097Jun 10 09:59 PM
SASSINE ANDYChief Financial OfficerJun 10Buy29.745,000148,700273,245Jun 10 09:59 PM
Ultragenyx Pharmaceutical Inc.DirectorMay 20Option Exercise16.00600,0009,600,0003,000,000May 22 01:41 PM
SASSINE ANDYChief Financial OfficerDec 05Buy9.735,64954,965268,245Dec 09 09:45 PM
SASSINE ANDYChief Financial OfficerDec 03Buy10.0010,000100,000257,596Dec 05 09:39 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.